Monitoring anticoagulation and inflammation in patients after heart and vascular surgery
Anticoagulation and Inflammation Monitoring in Patients After Heart and Vascular Interventions: Prospective Observational Study
This study is trying to find the best ways to monitor blood thinning treatments in patients after major heart and vascular surgeries to improve safety and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University Innsbruck Academic / other |
| Locations | 1 site (Innsbruck, Tyrol) |
| Trial ID | NCT06222866 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the most effective monitoring tools for unfractionated heparin (UFH) in patients undergoing major heart and vascular surgeries. It will compare various monitoring modalities, such as activated clotting time (ACT), activated partial thromboplastin time (aPTT), viscoelastic tests (ROTEM), and anti-Xa levels, to assess their association with adverse events like thrombosis and bleeding. Additionally, the study will explore the relationship between inflammation and delirium in these patients. By identifying the best monitoring practices, the study seeks to enhance patient safety and outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults over 17 scheduled for elective cardiac or vascular surgery requiring anticoagulation.
Not a fit: Patients who are pregnant or participating in other interventional clinical trials may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved anticoagulation management and reduced adverse events in patients undergoing heart and vascular interventions.
How similar studies have performed: While this study explores established monitoring techniques, the specific comparative approach to evaluate their effectiveness in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: \> 17 years * Informed written consent * Scheduled for cardiac intervention where the use of UFH is expected (elective surgery) * Scheduled for vascular intervention when the need for perioperative anticoagulation is expected (elective surgery) * Patients receiving ECMO support Exclusion Criteria: * Patients that are known to be pregnant * Known participation in other interventional clinical trial
Where this trial is running
Innsbruck, Tyrol
- Medical University Innsbruck — Innsbruck, Tyrol, Austria (Recruiting)
Study contacts
- Study coordinator: Sasa Rajsic, MD, PhD
- Email: sasa.rajsic@tirol-kliniken.at
- Phone: 004367763004447
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.